The case for & against
Bull & Bear analysis
Bullish
InterCure Ltd. (NASDAQ: INCR) is a leading medical cannabis company based in Israel, noted for its vertically integrated operations that encompass the cultivation, production, and sale of pharmaceutical-grade cannabis. As the largest licensed cannabis entity in Israel, InterCure is positioned to capitalize on both domestic growth and international expansion opportunities in light of evolving regulatory frameworks surrounding medical and recreational cannabis. The company is well-aligned with the increasing acceptance of cannabis products globally, fostering a strong industry presence.
Bull says
- ↑Q2 2022 revenue of $37 m grew >100% YoY, implying a $150 m run rate
- ↑Operations generated $20 m cash flow; $96 m cash on balance sheet
- ↑~30% share of Israel’s medical cannabis market drives pricing power
- ↑Anticipated prescription reforms could boost patient base by ~70%
- ↑Strong factor profile: positive earnings revisions, undervalued book-to-price, low volatility
Bear says
- ↓Negative earnings yield signals weak return potential on capital
- ↓Low institutional ownership and high short interest reflect skepticism
- ↓Regulatory uncertainties may limit physician prescribing and patient access
- ↓Intense competition forces price discounting; gross margin fell from 44% to 41%
- ↓International expansion into markets like Germany faces execution and regulatory hurdles
Earnings Call · Q3 2021 · Mgmt. Guidance
Updated 08-30-2026bullish
Transcript signals
Bull points
- We just reported another record revenue quarter of $25 million, an impressive growth close to three times greater than the third quarter of 2020 revenue of $9 million, and up by more than 36% sequentially compared to the second quarter of 2021.
- Revenue growth during the third quarter of 2021 reflects increased market share and growing consumer demand for our branded products, same-store sales growth, expansion, and the strength of our medical cannabis dispensing operations.
- On an apples to apples basis, excluding the impact of consolidating the trading house operation acquired last quarter, our normalized gross margin for the quarter reached approximately 45% compared to 42.6% in the second quarter of 2021, representing a better product mix as we are implementing our vertically integrated model and selling more throughout our dispensing operation.
Bear points
- we cannot provide specific numbers, you know, as we are moving through the integration model, which indicates uncertainty in margin improvement timelines
Read full transcript analysis ›